• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Academic patents and access to medicines in developing countries.学术专利与发展中国家的药品可及性。
Am J Public Health. 2009 Jan;99(1):9-17. doi: 10.2105/AJPH.2007.128769. Epub 2008 Nov 13.
2
The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.药品知识产权的困境：在确保穷人获得药品与遵守国际协定之间的矛盾。
Dev World Bioeth. 2003 May;3(1):27-48. doi: 10.1111/1471-8847.00058.
3
Taking TRIPS to India--Novartis, patent law, and access to medicines.前往印度的《与贸易有关的知识产权协定》之行——诺华公司、专利法与药品可及性
N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.
4
Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.专利绊脚：艾滋病、治疗可及性与制造稀缺
Conn J Int Law. 2002 Spring;17(2):157-248.
5
TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.《与贸易有关的知识产权协定》、药品专利与基本药物的获取：从西雅图到多哈的漫长之路
Chic J Int Law. 2002 Spring;3(1):27-46.
6
Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.专利必要性：生物技术领域的知识产权困境与发展中国家的治疗公平性
Houst J Int Law. 2002;24(2):227-78.
7
Introduction: Access to life-saving medicines and intellectual property rights.引言：获取救命药物与知识产权
Camb Q Healthc Ethics. 2011 Apr;20(2):277-8. doi: 10.1017/S0963180110000927.
8
Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.发展中国家与强制许可：在将投资副作用最小化的同时使基本药物可及性最大化。
J Law Med Ethics. 2009 Summer;37(2):209-21. doi: 10.1111/j.1748-720X.2009.00366.x.
9
Out-licensing: a practical approach for improvement of access to medicines in poor countries.对外许可：改善贫困国家药品可及性的实用方法。
Lancet. 2003 Jan 25;361(9354):341-4. doi: 10.1016/S0140-6736(03)12331-8.
10
Access to life-saving medicines and intellectual property rights: an ethical assessment.获取救命药物与知识产权：一项伦理评估。
Camb Q Healthc Ethics. 2011 Apr;20(2):279-89. doi: 10.1017/S0963180110000939.

引用本文的文献

1
Using Bayh-Dole Act March-In Rights to Lower US Drug Prices.利用《拜杜法案》的介入权降低美国药品价格。
JAMA Health Forum. 2024 Nov 1;5(11):e243775. doi: 10.1001/jamahealthforum.2024.3775.
2
NIH funding for patents that contribute to market exclusivity of drugs approved 2010-2019 and the public interest protections of Bayh-Dole.NIH 为有助于 2010-2019 年批准的药物市场独占性的专利提供资金以及拜杜法案的公共利益保护。
PLoS One. 2023 Jul 26;18(7):e0288447. doi: 10.1371/journal.pone.0288447. eCollection 2023.
3
Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.比较 2010-2019 年美国国立卫生研究院与制药行业在新药批准方面的研究支出。
JAMA Health Forum. 2023 Apr 7;4(4):e230511. doi: 10.1001/jamahealthforum.2023.0511.
4
Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms.比较学术机构与商业公司之间的生物技术许可证的经济条款。
PLoS One. 2023 Mar 31;18(3):e0283887. doi: 10.1371/journal.pone.0283887. eCollection 2023.
5
Commercialization of academic patents in Chinese universities: Antecedents and spatial spillovers.中国高校学术专利的商业化：影响因素与空间溢出效应
Heliyon. 2023 Mar 15;9(3):e14601. doi: 10.1016/j.heliyon.2023.e14601. eCollection 2023 Mar.
6
TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.走向何方的贸易相关知识产权协定？关于促进基本药物全球传播的知识产权许可模式实证文献的叙述性综述
Pharmaceutics. 2021 Dec 27;14(1):48. doi: 10.3390/pharmaceutics14010048.
7
Structural violence and the biomedical innovation system: what responsibility do universities have in ensuring access to health technologies?结构性暴力与生物医学创新体系：大学在确保健康技术可及性方面负有何种责任？
BMJ Glob Health. 2021 May;6(5). doi: 10.1136/bmjgh-2020-004916.
8
The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.美国学术界药物发现与开发的现状：工业界与学术界合作对药物发现与开发的影响。
Clin Transl Sci. 2018 Nov;11(6):597-606. doi: 10.1111/cts.12577. Epub 2018 Jul 30.
9
Contribution of NIH funding to new drug approvals 2010-2016.NIH 资助对 2010-2016 年新药批准的贡献。
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2329-2334. doi: 10.1073/pnas.1715368115. Epub 2018 Feb 12.
10
NIH inventions translate into drugs and biologics with high public health impact.美国国立卫生研究院（NIH）的发明转化为对公众健康有重大影响的药物和生物制品。
Nat Biotechnol. 2014 Jan;32(1):52-8. doi: 10.1038/nbt.2785.

本文引用的文献

1
The anatomy of medical school patenting.医学院校专利的剖析。
N Engl J Med. 2007 Nov 15;357(20):2049-56. doi: 10.1056/NEJMsa067417.
2
Leveraging university research to advance global health.利用大学研究推动全球健康。
JAMA. 2007 Oct 24;298(16):1934-6. doi: 10.1001/jama.298.16.1934.
3
Global framework on essential health R&D.基本卫生研究与开发全球框架
Lancet. 2006 May 13;367(9522):1560-1. doi: 10.1016/S0140-6736(06)68672-8.
4
Improving access to medicines in poor countries: the role of universities.改善贫困国家的药品可及性：大学的作用。
PLoS Med. 2006 Apr;3(6):e136. doi: 10.1371/journal.pmed.0030136.
5
Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?抗逆转录病毒药物的专利是否限制了非洲地区获得艾滋病治疗的机会？
JAMA. 2001 Oct 17;286(15):1886-92. doi: 10.1001/jama.286.15.1886.
6
Public-private interaction in pharmaceutical research.制药研究中的公私合作
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12725-30. doi: 10.1073/pnas.93.23.12725.
7
Global burden of the HIV pandemic.全球艾滋病大流行的负担。
Lancet. 1996 Jul 13;348(9020):99-106. doi: 10.1016/s0140-6736(96)01029-x.

学术专利与发展中国家的药品可及性。

Academic patents and access to medicines in developing countries.

作者信息

Sampat Bhaven N

机构信息

Department of Health Policy and Management, the International Center for Health Outcomes and Innovation Research, School of International and Public Affairs, Columbia University, 600 West 168th St, 7th Floor, New York, NY 10032, USA.

出版信息

Am J Public Health. 2009 Jan;99(1):9-17. doi: 10.2105/AJPH.2007.128769. Epub 2008 Nov 13.

DOI:10.2105/AJPH.2007.128769
PMID:19008514
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2636619/
Abstract

There is a widespread and growing concern that patents hinder access to life-saving drugs in developing countries. Recent student movements and legislative initiatives emphasize the potential role that research universities in developed countries could have in ameliorating this "access gap." These efforts are based on the assumption that universities own patents on a substantial number of drugs and that patents on these drugs are currently filed in developing countries. I provide empirical evidence regarding these issues and explore the feasibility and desirability of proposals to change university patenting and licensing practices to promote access to medicines in the developing world.

摘要

人们普遍且日益担忧专利会阻碍发展中国家获取救命药物。近期的学生运动和立法倡议强调了发达国家的研究型大学在缓解这种“获取差距”方面可能发挥的潜在作用。这些努力基于这样一种假设，即大学拥有大量药物的专利，并且这些药物的专利目前已在发展中国家提交申请。我提供了关于这些问题的实证证据，并探讨了改变大学专利申请和许可做法以促进发展中世界药品获取的提议的可行性和可取性。